Evidence supporting the use of: DMSA
For the health condition: Lead Poisoning

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Dimercaptosuccinic acid (DMSA) is scientifically validated as a chelating agent for the treatment of lead poisoning. Multiple randomized controlled trials and clinical guidelines support its use, especially in children with moderate blood lead levels (commonly above 45 µg/dL). DMSA acts by binding to lead ions in the body, forming water-soluble complexes that are eliminated via the urine, thereby reducing the body burden of lead.

The U.S. Food and Drug Administration (FDA) has approved DMSA (marketed as Succimer) for this indication, and the Centers for Disease Control and Prevention (CDC) includes it in their recommended protocols for treating pediatric lead poisoning. Compared to older chelators like EDTA or British anti-Lewisite (BAL), DMSA has a more favorable safety profile and is effective when administered orally, expanding its utility in outpatient settings. Studies, such as the Treatment of Lead-Exposed Children (TLC) trial, have confirmed its efficacy in reducing blood lead levels, although they have also indicated that chelation does not necessarily reverse neurocognitive deficits if exposure has already caused damage.

In summary, the use of DMSA for lead poisoning is based on robust scientific evidence, regulatory approval, and clinical practice guidelines internationally. Its role is well-established in medical toxicology for reducing body lead burden, especially in symptomatic patients or those with significant exposure.

More about DMSA
More about Lead Poisoning

Other health conditions supported by DMSA

Heavy Metal Poisoning
Lead Poisoning
Mercury Poisoning

Products containing DMSA

We currently have no products on Vitabase that contain this ingredient.